bioAffinity Other Wednesday, July 22, 2026 0.00 Neutral

bioAffinity partners with Pictor to develop COPD and asthma diagnostics

bioAffinity Technologies has partnered with Pictor to develop and commercialize diagnostic tests for asthma and COPD, creating a more comprehensive picture of lung inflammation. This collaboration increases laboratory throughput.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day